Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Predicting treatment responses earlier for brain tumor patients

Using metabolic or molecular imaging to measure brain tumor patients' response to treatment is a powerful predictor of survival, notes a first-of-its-kind study presented at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

5 Jun 2007

Patients around the world face stark inequalities in access to cancer treatment

The report's authors urge decision makers in every country to take action and ensure that everyone has equal access to new cancer drugs when they are needed, wherever they live.

10 May 2007

ESMO explores collaboration to fight cancer on all fronts

Leading figures in the global fight against lung cancer are meeting in the city of Geneva, Switzerland this week to discuss the latest tools for preventing and treating chest malignancies, which kill more than 1.3 million people each year.

2 Apr 2007

Avastin slows growth of gliomas

Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found.

20 Feb 2007

Brits denied new targeted bowel cancer drugs

Despite the fact that bowel cancer is the third most common form of the disease in Britain and kills 16,000 people every year, the government watchdog on drugs the National Institute for Health and Clinical Excellence (NICE) has sparked a bitter controversy by refusing to provide two bowel cancer drugs on the National Health Service (NHS) to cancer patients.

21 Aug 2006

Cancer stem cells spur glioma angiogenesis, could hold key to brain tumor therapy

Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel formation, and may hold the key to treating these deadly cancers.

15 Aug 2006

Trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer

Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin.) in combination with paclitaxel (Taxol.) survived without the disease getting worse for almost twice as long as patients who received paclitaxel alone.

23 Mar 2006

Avastin trial for pancreatic tumors

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti.

23 Feb 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage.

1 Nov 2005

Giving patients both chemotherapy and radiation in the beginning of treatment may help cancer patients live longer

While researchers have learned in the last decade that combining chemotherapy with radiation is better than radiation alone for treating non-small cell lung cancer patients with locally advanced disease - cancer confined to the lungs - finding the right combination of drugs - and the best timing of treatment - has been tricky.

6 Sep 2005

Tumor vasculature has become an attractive target in the treatment of cancer.

Treatment with a protein fused to an antibody in tumor-bearing mice led to coagulation of the blood within the tumor blood vessels, tumor tissue death, and tumor growth delay, according to a new study in the May 18 issue of the Journal of the National Cancer Institute.

17 May 2005

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

16 May 2005

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Patients with a particular type of advanced lung cancer may have a new option based on data presented at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

15 May 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Good results in new lung cancer treatment

Interim analysis of a Phase III study of Avastin (bevacizumab) with paclitaxel and carboplatin chemotherapies in first-line non-squamous, non-small cell lung cancer (NSCLC) met its primary goal of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alone.

15 Mar 2005

New cancer drug Avastin keeps cancer under control

Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps cancer under control for a significantly longer duration, even when used in a group of elderly patients with advanced colorectal cancer who are too sick to tolerate traditional aggressive chemotherapy.

1 Mar 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005